RECOTHROM features

100% free of human or animal plasma, Minimizes the risk of transmitting known and unknown blood-borne pathogens, No BLACK BOX* warning, Low incidence of specific anti-product antibody development**

*Based on available safety and immunogenicity data. Limited data are currently available on repeat exposure to RECOTHROM.

**N=5/552 (0.9%) of patients treated with RECOTHROM in clinical trials developed anti-product antibodies; none of these antibodies neutralized native human thrombin.